725 related articles for article (PubMed ID: 29174549)
41. Targeting the human macrophage with combinations of drugs and inhibitors of Ca2+ and K+ transport to enhance the killing of intracellular multi-drug resistant Mycobacterium tuberculosis (MDR-TB)--a novel, patentable approach to limit the emergence of XDR-TB.
Martins M
Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):110-7. PubMed ID: 21517742
[TBL] [Abstract][Full Text] [Related]
42. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
43. [Comparative genomic analysis of peruvian strains of Mycobacterium tuberculosis].
Tarazona D; Galarza M; Levano KS; Guio H
Rev Peru Med Exp Salud Publica; 2016 Jun; 33(2):256-63. PubMed ID: 27656924
[TBL] [Abstract][Full Text] [Related]
44. Metabolic pathway analysis approach: identification of novel therapeutic target against methicillin resistant Staphylococcus aureus.
Uddin R; Saeed K; Khan W; Azam SS; Wadood A
Gene; 2015 Feb; 556(2):213-26. PubMed ID: 25436466
[TBL] [Abstract][Full Text] [Related]
45. Genome Analysis of the First Extensively Drug-Resistant (XDR) Mycobacterium tuberculosis in Malaysia Provides Insights into the Genetic Basis of Its Biology and Drug Resistance.
Kuan CS; Chan CL; Yew SM; Toh YF; Khoo JS; Chong J; Lee KW; Tan YC; Yee WY; Ngeow YF; Ng KP
PLoS One; 2015; 10(6):e0131694. PubMed ID: 26110649
[TBL] [Abstract][Full Text] [Related]
46. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from high prevalence tuberculosis states in Mexico.
Juarez-Eusebio DM; Munro-Rojas D; Muñiz-Salazar R; Laniado-Laborín R; Martinez-Guarneros JA; Flores-López CA; Zenteno-Cuevas R
Infect Genet Evol; 2017 Nov; 55():384-391. PubMed ID: 27637930
[TBL] [Abstract][Full Text] [Related]
47. Importance of differential identification of Mycobacterium tuberculosis strains for understanding differences in their prevalence, treatment efficacy, and vaccine development.
Chae H; Shin SJ
J Microbiol; 2018 May; 56(5):300-311. PubMed ID: 29721826
[TBL] [Abstract][Full Text] [Related]
48. Prevalence of resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients in Viet Nam, 2011.
Nguyen HB; Nguyen NV; Tran HT; Nguyen HV; Bui QT
Western Pac Surveill Response J; 2016; 7(2):35-40. PubMed ID: 27508089
[TBL] [Abstract][Full Text] [Related]
49. Unusual regioversatility of acetyltransferase Eis, a cause of drug resistance in XDR-TB.
Chen W; Biswas T; Porter VR; Tsodikov OV; Garneau-Tsodikova S
Proc Natl Acad Sci U S A; 2011 Jun; 108(24):9804-8. PubMed ID: 21628583
[TBL] [Abstract][Full Text] [Related]
50. Characterization of the genetic diversity of extensively-drug resistant Mycobacterium tuberculosis clinical isolates from pulmonary tuberculosis patients in Peru.
Cáceres O; Rastogi N; Bartra C; Couvin D; Galarza M; Asencios L; Mendoza-Ticona A
PLoS One; 2014; 9(12):e112789. PubMed ID: 25489950
[TBL] [Abstract][Full Text] [Related]
51. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
[TBL] [Abstract][Full Text] [Related]
52. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.
Blöndal K; Viiklepp P; Guðmundsson LJ; Altraja A
Int J Tuberc Lung Dis; 2012 Sep; 16(9):1228-33. PubMed ID: 22748131
[TBL] [Abstract][Full Text] [Related]
53. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
[TBL] [Abstract][Full Text] [Related]
54. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
55. Quadruple-first line drug resistance in Mycobacterium tuberculosis in Vietnam: What can we learn from genes?
Nguyen HQ; Nguyen NV; Contamin L; Tran THT; Vu TT; Nguyen HV; Nguyen NLT; Nguyen ST; Dang AD; Bañuls AL; Nguyen VAT
Infect Genet Evol; 2017 Jun; 50():55-61. PubMed ID: 28214557
[TBL] [Abstract][Full Text] [Related]
56. Exploring functional genomics for the development of novel intervention strategies against tuberculosis.
Rachman H; Kaufmann SH
Int J Med Microbiol; 2007 Nov; 297(7-8):559-67. PubMed ID: 17467338
[TBL] [Abstract][Full Text] [Related]
57. Extensively drug-resistant tuberculosis at a tuberculosis specialist hospital in Shanghai, China: clinical characteristics and treatment outcomes.
Tang S; Zhang Q; Yu J; Liu Y; Sha W; Sun H; Fan L; Gu J; Hao X; Yao L; Xiao H
Scand J Infect Dis; 2011 Apr; 43(4):280-5. PubMed ID: 21247226
[TBL] [Abstract][Full Text] [Related]
58. Extensively drug-resistant tuberculosis in california, 1993-2006.
Banerjee R; Allen J; Westenhouse J; Oh P; Elms W; Desmond E; Nitta A; Royce S; Flood J
Clin Infect Dis; 2008 Aug; 47(4):450-7. PubMed ID: 18616396
[TBL] [Abstract][Full Text] [Related]
59. Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa.
Streicher EM; Müller B; Chihota V; Mlambo C; Tait M; Pillay M; Trollip A; Hoek KG; Sirgel FA; Gey van Pittius NC; van Helden PD; Victor TC; Warren RM
Infect Genet Evol; 2012 Jun; 12(4):686-94. PubMed ID: 21839855
[TBL] [Abstract][Full Text] [Related]
60. Extensively drug-resistant tuberculosis: new strains, new challenges.
Banerjee R; Schecter GF; Flood J; Porco TC
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):713-24. PubMed ID: 18847407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
